JP2014505463A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505463A5
JP2014505463A5 JP2013538829A JP2013538829A JP2014505463A5 JP 2014505463 A5 JP2014505463 A5 JP 2014505463A5 JP 2013538829 A JP2013538829 A JP 2013538829A JP 2013538829 A JP2013538829 A JP 2013538829A JP 2014505463 A5 JP2014505463 A5 JP 2014505463A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cysteine
cysteines
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538829A
Other languages
English (en)
Japanese (ja)
Other versions
JP6014596B2 (ja
JP2014505463A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059775 external-priority patent/WO2012064733A2/en
Publication of JP2014505463A publication Critical patent/JP2014505463A/ja
Publication of JP2014505463A5 publication Critical patent/JP2014505463A5/ja
Application granted granted Critical
Publication of JP6014596B2 publication Critical patent/JP6014596B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538829A 2010-11-09 2011-11-08 均一コンジュゲーションのための抗体足場 Expired - Fee Related JP6014596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41158810P 2010-11-09 2010-11-09
US61/411,588 2010-11-09
PCT/US2011/059775 WO2012064733A2 (en) 2010-11-09 2011-11-08 Antibody scaffold for homogenous conjugation

Publications (3)

Publication Number Publication Date
JP2014505463A JP2014505463A (ja) 2014-03-06
JP2014505463A5 true JP2014505463A5 (enExample) 2014-12-25
JP6014596B2 JP6014596B2 (ja) 2016-10-25

Family

ID=46051511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538829A Expired - Fee Related JP6014596B2 (ja) 2010-11-09 2011-11-08 均一コンジュゲーションのための抗体足場

Country Status (4)

Country Link
US (2) US20130330350A1 (enExample)
EP (1) EP2638066A4 (enExample)
JP (1) JP6014596B2 (enExample)
WO (1) WO2012064733A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー/エス 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
US9700638B2 (en) 2012-05-08 2017-07-11 Rutgers, The State University Of New Jersey Near infrared label and methods of use thereof
SG10201706468RA (en) * 2013-02-08 2017-09-28 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2014166029A1 (zh) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
LT2991683T (lt) 2013-05-02 2019-12-27 Glykos Finland Oy Glikoproteino arba glikano konjugatai su toksine medžiaga
EP2999408B1 (en) * 2013-05-08 2020-04-22 Rutgers, the State University of New Jersey Ddao derivatives and their use
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015069794A2 (en) 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use
MX2016007369A (es) 2013-12-12 2016-09-08 Stemcentrx Inc Nuevos anticuerpos anti-dpep3 y metodos de uso.
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SI4212552T1 (sl) 2014-01-31 2025-03-31 Daiichi Sankyo Co., Ltd. Konjugat protitelesa-zdravila anti-her2
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP4190809A1 (en) 2014-02-11 2023-06-07 Seagen Inc. Selective reduction of proteins
AU2015218633A1 (en) 2014-02-21 2016-09-01 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3129063B1 (en) * 2014-04-10 2021-01-27 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160251417A1 (en) * 2015-01-22 2016-09-01 Prothena Biosciences Limited Antibodies recognizing medin
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506407D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506394D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506399D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2938186T3 (es) 2015-06-29 2023-04-05 Daiichi Sankyo Co Ltd Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018110515A1 (ja) 2016-12-12 2018-06-21 第一三共株式会社 抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
KR102322530B1 (ko) * 2017-02-08 2021-11-05 화이자 인코포레이티드 캡핑된 및 비-캡핑된 항체 시스테인의 대규모 제조 공정 및 치료 단백질 접합에서의 그의 용도
KR20240074000A (ko) 2017-02-28 2024-05-27 다이이찌 산쿄 가부시키가이샤 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
HRP20221063T1 (hr) 2017-04-18 2022-11-11 Medimmune Limited Konjugati pirolobenzodiazepina
PL3612234T3 (pl) 2017-04-20 2024-09-02 Adc Therapeutics Sa Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
TW202532105A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
CN111065638B (zh) 2017-08-18 2021-04-09 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
EP3710066B1 (en) 2017-11-14 2022-06-08 Medimmune Limited Pyrrolobenzodiazepine conjugates
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
AU2019248547B2 (en) 2018-04-02 2025-07-17 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108642176B (zh) * 2018-04-12 2021-11-09 江门市中心医院 Part1作为乳腺癌诊断、治疗以及预后标志物的应用
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
WO2019224340A1 (en) 2018-05-25 2019-11-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体-薬物コンジュゲートの薬物部位を認識する蛋白質
KR102894505B1 (ko) 2018-07-31 2025-12-02 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료
BR112021005246A2 (pt) 2018-09-20 2021-06-15 Daiichi Sankyo Company, Limited agente terapêutico, e, método de tratamento para câncer
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
AU2020242747B2 (en) 2019-03-15 2025-09-18 Medimmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CN110596387B (zh) * 2019-09-20 2020-06-12 四川大学华西医院 Cox10自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途
CN121219016A (zh) 2023-06-02 2025-12-26 第一三共株式会社 抗-her3抗体-药物缀合物和rasg12c抑制剂的组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951062B2 (ja) * 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1791565T1 (sl) * 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
WO2006065533A2 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US9322035B2 (en) * 2007-05-31 2016-04-26 Genmab A/S Recombinant IgG4 monovalent antibodies
ES2613963T3 (es) * 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio

Similar Documents

Publication Publication Date Title
JP2014505463A5 (enExample)
JP2020503891A5 (enExample)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
RU2016151265A (ru) Антитела, направленные на cd127
EP2826791A3 (en) Humanized anti-C5aR antibodies
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EP4483963A3 (en) Monoclonal antibodies against c-met
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
SI2771031T1 (en) Humanized antibodies that recognize alpha-synuclein
RU2019119442A (ru) Новый коньюгат аманитина
RU2017102193A (ru) Конструкции полиспецифических антител
EA201100923A1 (ru) Антитела человека против тканевого фактора
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
IN2014CN03936A (enExample)
JP2016527314A5 (enExample)
EP3539988A3 (en) Monoclonal antibodies against her2
JP2014519524A5 (enExample)
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
EP3839049A3 (en) Antibodies, variable domains & chains tailored for human use
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1